Sign up to our newsletter Subscribe
We found for
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations

Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies

The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment

Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
